Healthcare ❯ Pharmaceuticals ❯ Drug Development

Market Trends

GLP-1 Drugs Sales Performance Eli Lilly Investment Opportunities Semaglutide FDA Approvals Patent Expiration

iShares' Healthcare and Pharmaceuticals ETFs Share Fees as Fidelity's FHLC Undercuts Rivals

Recent fund comparisons show fee parity at iShares while cost, concentration and yield gaps should guide whether investors favor broad low‑cost ETFs or concentrated drugmaker exposure.

11 ARTICLES

3mo ago

Healthcare ETFs Force a Choice Between Low Cost and Higher Growth

7 ARTICLES

5mo ago

Pfizer Posts Higher Q1 Sales but Lower Profit, Raising Fresh Questions About Its Dividend

3 ARTICLES

9mo ago

Roche Posts 2025 CER Growth but Misses Profit Forecast as Strong Franc Weighs